CG Oncology (CGON) Common Equity (2023 - 2026)

CG Oncology's Common Equity history runs 4 years deep, the most recent figure standing at $1.1 billion for Q1 2026.

• Quarterly Common Equity rose 54.92% year-over-year to $1.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 54.92% YoY) and the FY2025 annual result came in at $752.6 million, up 2.62% from the prior year.
• Common Equity was $1.1 billion for Q1 2026 at CG Oncology, up from $752.6 million in the prior quarter.
• Across five years, Common Equity topped out at $1.1 billion in Q1 2026 and bottomed at -$123.1 million in Q4 2023.
• A 4-year average of $452.6 million and a median of $568.9 million in 2024 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2024 — Common Equity jumped 760.66% — and 2025, when it grew 2.62%.
• CG Oncology's Common Equity stood at -$123.1 million in 2023, then surged by 695.76% to $733.4 million in 2024, then advanced by 2.62% to $752.6 million in 2025, then surged by 45.07% to $1.1 billion in 2026.
• Business Quant data shows CGON's Common Equity at $1.1 billion in Q1 2026, $752.6 million in Q4 2025, and $687.6 million in Q3 2025.